(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
-1.48% $ 0.700
Live Chart Being Loaded With Signals
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 24 044.00 |
Średni wolumen | 210 019 |
Kapitalizacja rynkowa | 18.98M |
EPS | $0 ( 2024-04-26 ) |
Następna data zysków | ( $-0.410 ) 2024-06-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.620 |
ATR14 | $0.00700 (0.98%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-03 | Schambye Hans T. | Buy | 200 000 | Restricted Stock Units |
2024-01-03 | Winslow Garrett | Buy | 100 000 | Restricted Stock Units |
2024-01-03 | Freve Jonathan | Buy | 100 000 | Restricted Stock Units |
2023-08-15 | Orbimed Advisors Llc | Sell | 535 534 | Common Stock |
2023-08-15 | Orbimed Advisors Llc | Sell | 248 819 | Common Stock |
INSIDER POWER |
---|
-13.36 |
Last 96 transactions |
Buy: 4 275 597 | Sell: 1 504 628 |
Wolumen Korelacja
Galecto, Inc. Korelacja
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Galecto, Inc. Korelacja - Waluta/Towar
Galecto, Inc. Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-830 000 (0.00 %) |
EPS: | $-1.440 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-830 000 (0.00 %) |
EPS: | $-1.440 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-490 000 (0.00 %) |
EPS: | $-2.44 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.05 |
Financial Reports:
No articles found.
Galecto, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej